Kaletra Monotherapy in HIV/HCV Co-infected Subjects
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The study has been designed to test the hypothesis that in patients co-infected with HIV and
HCV who exhibit maximal virologic suppression on a double class antiretroviral (ARV) regimen,
including two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and a Non-nucleoside
Reverse Transcriptase Inhibitors (NNRTI) or a Protease Inhibitor (PI) (boosted or not with
ritonavir), simplification of highly active antiretroviral therapy (HAART) to Kaletra®
monotherapy will represent a viable strategy without any negative impact on the virologic
control of HIV infection.